Abstract
The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adjuvants, Immunologic*
-
Adolescent
-
Adult
-
Antibodies, Viral / blood*
-
Antibodies, Viral / immunology
-
Double-Blind Method
-
Drug Combinations
-
Female
-
Humans
-
Influenza A Virus, H5N1 Subtype / immunology*
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / immunology*
-
Influenza, Human / immunology
-
Influenza, Human / prevention & control
-
Male
-
Middle Aged
-
Polysorbates / administration & dosage
-
Squalene / administration & dosage
-
Squalene / immunology*
-
Time Factors
-
Vaccination / adverse effects
-
Young Adult
-
alpha-Tocopherol / administration & dosage
-
alpha-Tocopherol / immunology*
Substances
-
Adjuvants, Immunologic
-
Antibodies, Viral
-
Drug Combinations
-
Influenza Vaccines
-
Polysorbates
-
Squalene
-
AS03 adjuvant
-
alpha-Tocopherol